Supernus Pharmaceuticals (NASDAQ: SUPN) has recently undergone a series of notable rating adjustments from various financial institutions. This activity reflects the shifting perspectives on the company’s stock amid a fluctuating market environment.
On December 19, 2025, analysts at Stifel Nicolaus raised their price target for Supernus Pharmaceuticals from $50.00 to $55.00, maintaining a “hold” rating on the stock. This follows a pattern of cautious optimism, as the company has seen several reaffirmations of lower ratings from other firms. For instance, on December 15, Weiss Ratings reaffirmed its “sell (d+)” rating, a sentiment echoed multiple times throughout December.
Earlier, on December 8, Zacks Research downgraded Supernus from a “strong-buy” to a “hold” rating. This downgrade came on the heels of a series of negative evaluations by Weiss Ratings, which had reiterated the “sell (d+)” rating on multiple occasions throughout November and December. The most significant of these occurred on November 13, when Weiss downgraded the rating from “hold (c+)” to “sell (d+)”.
In addition to the rating changes, insider transactions have also raised eyebrows. On December 19, senior vice president Frank Mottola sold 20,000 shares of Supernus stock at an average price of $50.41, totaling approximately $1,008,200. Following this transaction, Mottola’s remaining shares in the company decreased to 15,496, valued at around $781,153.36, marking a 56.34% reduction in his ownership.
Vice President Padmanabh P. Bhatt also engaged in selling activity, offloading 710 shares on December 18 at an average price of $44.44, resulting in a total value of $31,552.40. Bhatt’s transaction reflected a 4.67% decrease in his stake in the company, leaving him with 14,508 shares valued at approximately $644,735.52.
Over the past three months, Supernus insiders have sold a total of 90,845 shares valued at around $4,560,380. Company insiders now hold 8.80% of the company’s stock, a significant point of interest for potential investors.
Supernus Pharmaceuticals markets a range of products, including Trokendi XR and Oxtellar XR, both extended-release antiepileptic medications aimed at maintaining stable drug levels for seizure control. Additionally, the company offers Qelbree, an extended-release capsule approved for treating attention-deficit/hyperactivity disorder (ADHD) in both pediatric and adult patients.
As the market continues to react to these developments, investors are closely monitoring Supernus Pharmaceuticals for further insights into its performance and potential future adjustments in analyst ratings.
